Evoke Pharma's basic earnings per share (Basic EPS) for the
three
months ended in Dec. 2024 was $-0.80.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.71.
Evoke Pharma's EPS (Diluted) for the
three
months ended in Dec. 2024 was $-0.80.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.71.
Evoke Pharma's EPS without NRI for the
three
months ended in Dec. 2024 was $-0.80.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -4.71.
During the past 3 years, the average EPS without NRIGrowth Rate was 58.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 38.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 30.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Evoke Pharma's highest 3-Year average EPS without NRI Growth Rate was 58.30% per year. The lowest was -1.40% per year. And the median was 18.00% per year.
Evoke Pharma EPS (Basic) Historical Data
The historical data trend for Evoke Pharma's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Evoke Pharma's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoke Pharma (NAS:EVOK) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Evoke Pharma EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Evoke Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVOK has been successfully added to your 